Inhibition of MDR1 overcomes resistance to brentuximab vedotin in Hodgkin lymphoma

PURPOSE: In classical Hodgkin lymphoma (HL), the malignant Reed-Sternberg cells express the cell surface marker CD30. Brentuximab vedotin (BV) is an antibody-drug conjugate that selectively delivers a potent cytotoxic agent, monomethyl auristatin E (MMAE), to CD30-positive cells. Although BV elicits...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Chen, Robert, Herrera, Alex F., Hou, Jessie, Chen, Lu, Wu, Jun, Guo, Yuming, Synold, Timothy W., Ngo, Vu N., Puverel, Sandrine, Mei, Matthew, Popplewell, Leslie, Yi, Shuhua, Song, Joo Y., Tao, Shu, Wu, Xiwei, Chan, Wing C, Forman, Stephen J., Kwak, Larry W., Rosen, Steven T., Newman, Edward M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7056527/
https://ncbi.nlm.nih.gov/pubmed/31811017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1768
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados